Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Sep 27, 2014; 6(9): 670-676
Published online Sep 27, 2014. doi: 10.4254/wjh.v6.i9.670
Published online Sep 27, 2014. doi: 10.4254/wjh.v6.i9.670
Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma
Masako Shomura, Department of Nursing, Tokai University School of Health Sciences, Isehara, Kanagawa 2591193, Japan
Tatehiro Kagawa, Koichi Shiraishi, Shunji Hirose, Yoshitaka Arase, Tetsuya Mine, Division of Gastroenterology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Kanagawa 2591193, Japan
Jun Koizumi, Department of Radiology, Tokai University School of Medicine, Isehara, Kanagawa 2591193, Japan
Author contributions: Shomura M and Kagawa T contributed equally to this study; Shomura M, Kagawa T, Shiraisi K, Hirose S and Arase Y performed the majority of sorafenib therapy; Koizumi J and Kagawa T provided evaluation the efficacy of therapy; Shomura M and Kagawa T provided the collection of all the data in addition to performing a statistical analysis and were also involved in writing and editing the manuscript; Shomura M provided financial support for this work; Mine T designed and coordinated the study.
Supported by Japan Society for the Promotion of Science (JSPS) KAKENHI Grant-in-Aid for Young Scientists (B) 21792240
Correspondence to: Masako Shomura, RN, PhD, Associate Professor, Department of Nursing, Tokai University School of Health Sciences, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan. rocky36j@is.icc.u-tokai.ac.jp
Telephone: +81-463-902035 Fax: +81-463-902035
Received: May 16, 2014
Revised: July 16, 2014
Accepted: August 27, 2014
Published online: September 27, 2014
Revised: July 16, 2014
Accepted: August 27, 2014
Published online: September 27, 2014
Core Tip
Core tip: Sorafenib therapy for advanced hepatocellular carcinoma (HCC) often causes adverse events (AEs), subsequently leading to dose reduction or discontinuation. Conversely, few studies have associated serious AEs with a favorable response to sorafenib. We aimed to elucidate the relationship between AEs occurrence, therapeutic efficacy, and the impact of nursing intervention on adherence to therapy. We observed that skin toxicity was associated with favorable outcomes in sorafenib therapy for advanced HCC. Furthermore nursing intervention contributed to better adherence, which may improve the efficacy of sorafenib therapy.